Literature DB >> 8730976

Stimulatory as well as inhibitory effects of ethinyloestradiol on the metabolic clearances of propranolol in young women.

T Walle1, T C Fagan, U K Walle, M J Topmiller.   

Abstract

1. The metabolism of a single 80 mg oral dose of propranolol was determined in nine young women before and after administration of ethinyloestradiol alone (EE2) or in combination with norethindrone (OC). 2. Whereas the total clearance of propranolol (2713 +/- 404 ml min-1 (mean +/- s.e.mean)) was not significantly altered by either EE2 (3365 +/- 347 ml min-1) or the combined OC (2905 +/- 345 ml min-1), significant changes in all three primary metabolic pathways were observed. 3. The clearance through side-chain oxidation decreased from 345 +/- 55 ml min-1 to 262 +/- 33 ml min-1 after EE2 (P < 0.05). A similar reduction of cytochrome P450 metabolism by EE2 has been observed for other drugs. 4. The clearance through glucuronidation increased from 364 +/- 61 ml min-1 to 625 +/- 117 ml min-1 after EE2 (P < 0.01). Similar stimulation of glucuronic acid conjugation by EE2 has also been observed for other drugs. 5. The clearance through ring oxidation increased from 697 +/- 109 ml min-1 to 1280 +/- 162 ml min-1 after EE2 (P < 0.01). This observation appears to be a novel finding with EE2 and cytochrome P450 metabolism. 6. The treatment with OC produced changes in propranolol's metabolic clearances which were qualitatively similar to those generated by EE2.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730976      PMCID: PMC2042593          DOI: 10.1046/j.1365-2125.1996.03097.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.

Authors:  S Hägg; O Spigset; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

Review 2.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

Authors:  Hongjian Zhang; Donghui Cui; Bonnie Wang; Yong-Hae Han; Praveen Balimane; Zheng Yang; Michael Sinz; A David Rodrigues
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects.

Authors:  Jagdev Sidhu; Sarah Job; Sunita Singh; Richard Philipson
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

Review 4.  Sex differences in the pharmacokinetics of antidepressants: influence of female sex hormones and oral contraceptives.

Authors:  Valérie A Damoiseaux; Johannes H Proost; Vincent C R Jiawan; Barbro N Melgert
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

5.  Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population.

Authors:  J M Hoskins; G M Shenfield; A S Gross
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

6.  Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination.

Authors:  H Jeong; S Choi; J W Song; H Chen; J H Fischer
Journal:  Xenobiotica       Date:  2008-01       Impact factor: 1.908

7.  Evaluation of the Potential Pharmacokinetic Interactions Between Vixotrigine and an Oral Contraceptive.

Authors:  Yuan Zhao; Mark Versavel; Beth Tidemann-Miller; Romy Christmann; Himanshu Naik
Journal:  Clin Drug Investig       Date:  2020-08       Impact factor: 2.859

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.